Bio-Rad Laboratories Inc, Hercules, Calif, has launched a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs pembrolizumab (Keytruda) and nivolumab (Opdivo). When used in bioanalytical assays, the anti-pembrolizumab and anti-nivolumab antibodies enable clinicians to monitor drug levels in cancer patients.
Pembrolizumab and nivolumab are approved for the treatment of multiple cancers, including head and neck squamous cell carcinoma, metastatic melanoma, and non-small cell lung cancer. Bio-Rad’s anti-pembrolizumab and anti-nivolumab antibodies function by inhibiting binding with the target, programmed cell death protein 1 (PD-1), allowing for detection of the free drug.
“We are pleased to introduce three anti-pembrolizumab and five anti-nivolumab recombinant monoclonal anti-idiotypic antibodies, each of which is highly specific for pembrolizumab and nivolumab, respectively,” says Amanda Turner, Bio-Rad product manager. “The antibodies are ideal for the development of pharmacokinetic bridging ELISAs, as well as for use as reference standards in anti-drug antibody assays.”
Bio-Rad generates anti-idiotypic antibodies using the human combinatorial antibody library (HuCAL) and CysDisplay, a proprietary method of phage display, to yield a consistent, secure supply of highly targeted reagents.
The anti-pembrolizumab and anti-nivolumab antibodies are approved for in vitro research and commercial applications to support preclinical and clinical drug development, as well as for patient monitoring.
For more information visit Bio-Rad.